Frédéric Baribaud

Bristol-Myers Squibb (Germany) — Germany

Medicine · Health Sciences

47h-index8.6kcitations136works1.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Asthma and respiratory diseases(38), HIV Research and Treatment(23), Immune Cell Function and Interaction(21), Immunotherapy and Immune Responses(18), IL-33, ST2, and ILC Pathways(17)

Publications134 total

Benchmarking single-sample gene set scoring methods for application in precision medicine
Briefings in Bioinformatics·2025Open Access
Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Afimetoran, a Toll‐Like Receptor 7 and 8 Inhibitor, in Patients With Cutaneous Lupus Erythematosus: A Phase 1b Randomized, Double‐Blind, Placebo‐Controlled Study
ACR Open Rheumatology·2025· 7 citedOpen Access
POS1365 IN VITRO AND IN VIVO EVIDENCE OF THE STEROID-SPARING POTENTIAL OF AFIMETORAN, AN EQUIPOTENT TOLL-LIKE RECEPTOR 7/8 DUAL ANTAGONIST
Annals of the Rheumatic Diseases·2025Open Access
Su1833: SYMPTOM RESPONSE TRAJECTORY ANALYSIS IDENTIFIES DISTINCT SUBPOPULATIONS IN MODERATE-TO-SEVERE ULCERATIVE COLITIS LINKED TO MAINTENANCE OUTCOMES: A PATIENT LEVEL POST-HOC ANALYSIS OF 2,378 PARTICIPANTS ACROSS 6 RCT’S WITH 8 ADVANCED THERAPIES
Gastroenterology·2025
P0694 Clinical response trajectories identify distinct subpopulations of ulcerative colitis patients and are linked to disease outcome across different therapy classes. Patient level analysis of 2378 participants from 6 randomized controlled trials in moderate-severe UC representing 8 different mechanisms of action.
Journal of Crohn s and Colitis·2025· 1 citedOpen Access
Pharmacodynamic effects and exploratory efficacy of afimetoran, a TLR7/8 inhibitor, in patients with cutaneous lupus erythematosus
SKIN The Journal of Cutaneous Medicine·2024· 1 citedOpen Access
Abstract 4140427: Potassium-sparing Diuresis and Natriuresis With a Novel Renal Outer Medullary Potassium Channel Inhibitor, in Healthy Adult Participants
Circulation·2024
First‐in‐Human Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of BMS‐986308: A Renal Outer Medullary Potassium Channel Inhibitor
Clinical Pharmacology & Therapeutics·2024Open Access
788 Pharmacodynamic biomarkers of an IL-2 mutein following administration in healthy volunteers and patients with psoriasis
Journal of Investigative Dermatology·2024Open Access
POS0551 PHARMACODYNAMIC EFFECTS AND EXPLORATORY EFFICACY OF AFIMETORAN, A TLR7/8 INHIBITOR, IN PATIENTS WITH CUTANEOUS LUPUS ERYTHEMATOSUS
Annals of the Rheumatic Diseases·2024· 5 cited
Using an electronic diary and wristband accelerometer to detect exacerbations and activity levels in COPD: a feasibility study
ERJ Open Research·2023· 3 citedOpen Access
<i>Haemophilus influenzae</i> and <i>Moraxella catarrhalis</i> in sputum of severe asthma with inflammasome and neutrophil activation
Allergy·2023· 33 citedOpen Access
POS1129 IN VITRO EVIDENCE DEMONSTRATES THAT AFIMETORAN (BMS-986256), AN EQUIPOTENT TLR7/8 DUAL ANTAGONIST, HAS STEROID-SPARING POTENTIAL IN THE CLINIC
Annals of the Rheumatic Diseases·2023· 3 citedOpen Access
H influenzae &amp; M catarrhalis in sputum of severe asthma with inflammasome and neutrophil activation
2022· 1 citedOpen Access
Publisher Correction to: Collagen Turnover Biomarkers Associate with Active Psoriatic Arthritis and Decrease with Guselkumab Treatment in a Phase 3 Clinical Trial (DISCOVER-2)
Rheumatology and Therapy·2022· 1 citedOpen Access
Clinical and transcriptomic features of persistent exacerbation‐prone severe asthma in U‐BIOPRED cohort
Clinical and Translational Medicine·2022· 21 citedOpen Access
Collagen Turnover Biomarkers Associate with Active Psoriatic Arthritis and Decrease with Guselkumab Treatment in a Phase 3 Clinical Trial (DISCOVER-2)
Rheumatology and Therapy·2022· 25 citedOpen Access
Urinary metabotype of severe asthma evidences decreased carnitine metabolism independent of oral corticosteroid treatment in the U-BIOPRED study
European Respiratory Journal·2021· 29 citedOpen Access
POS1036 COLLAGEN TURNOVER MARKERS ARE ASSOCIATED WITH ACTIVE PSORIATIC ARTHRITIS AND DECREASE WITH GUSELKUMAB TREATMENT IN A PHASE-3 CLINICAL TRIAL
Annals of the Rheumatic Diseases·2021· 1 citedOpen Access
Suppression of Serum Interferon‐γ Levels as a Potential Measure of Response to Ustekinumab Treatment in Patients With Systemic Lupus Erythematosus
Arthritis & Rheumatology·2020· 25 citedOpen Access
page 1 of 7Next →

Frequent Co-authors

Robert W. Doms(20), Stefan Pöhlmann(14), Matthew J. Loza(12), Peter J. Sterk(8), Ratko Djukanović(8), George J. Leslie(7), Pascal Chanez(7), Ian M. Adcock(7), Kian Fan Chung(7), Yike Guo(7), James A. Hoxie(7), Terri G. Edwards(7), Carrie Brodmerkel(6), Bertrand De Meulder(6), Aruna T. Bansal(6), Ana R. Sousa(6), Julie Corfield(6), Charles Auffray(6), Elliot S. Barnathan(6), Diane Lefaudeux(5)